ChinaDaily Briefs

Daily Brief China: Eoptolink Technology Inc Ltd, Kelun Biotech, Chindata Group, Alibaba (ADR), HighTide Therapeutics, China SCE, PDD Holdings Inc, Syngenta Group, Unisound AI Technology and more

In today’s briefing:

  • ChiNext/​​​ChiNext50 Index Rebalance Preview: Potential Changes & Basket Performance
  • Kelun-Biotech (科伦博泰) IPO Trading: Lukewarm Demand but Peers Have Done Well Recently
  • Chindata (CD US): China Merchants Capital’s Rival Privatisation Offer
  • [Alibaba (BABA US, BUY, TP US$116) Target Price Change]: CMR Improves on Expanded Merchant Base
  • Pre-IPO HighTide Therapeutics – Its Outlook in NASH Field Is Not Optimistic, with High Risks
  • Morning Views Asia: China SCE, Hopson Development, Reliance Industries, Sino-Ocean Service
  • PDD Holdings Inc.: 3 Major Factors Responsible For Its Recovery – Key Drivers
  • Syngenta Pre-IPO – The Positives – Giant in the Agriculture Industry Set to Benefit from Policies
  • Unisound AI Technology Pre-IPO Tearsheet


ChiNext/​​​ChiNext50 Index Rebalance Preview: Potential Changes & Basket Performance

By Brian Freitas

  • One third of the way through the review period, we forecast 10 changes for the ChiNext Index (SZ399006 INDEX EQUITY) and 5 changes for the ChiNext 50 Index in December.
  • Passive trackers are estimated to trade around +/-0.5 days ADV on most of the potential adds/deletes, though there are some deletes that will have over 1 day ADV to sell.
  • The potential inclusion to one or both indices have outperformed the potential deletes by a huge margin in the 5 months. We’d wait for a pullback to re-enter positions.

Kelun-Biotech (科伦博泰) IPO Trading: Lukewarm Demand but Peers Have Done Well Recently

By Ke Yan, CFA, FRM

  • Kelun-Biotech raised HKD 1,259m (USD 161m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday, July 10th.
  • In our previous note, we looked at the company’s business lines of ADC products. We were of the view that the IPO is fairly priced, at best.
  • In this note, we provide an update for the IPO before trading debut.

Chindata (CD US): China Merchants Capital’s Rival Privatisation Offer

By Arun George

  • China Merchants Capital (CMC) disclosed a competing preliminary non-binding proposal to acquire Chindata Group (CD US) at US$9.20 per ADS, a 15.0% premium to Bain Capital’s US$8.00 per ADS offer.
  • Astonishingly, Chindata did not publicly disclose the CMC offer, which was sent to the special committee on 9 June, i.e., 34 days ago.
  • CMC must get Bain Capital’s support due to its 92.34% voting rights. The presence of a credible competing proposal will require Bain Capital to match CMC’s offer.

[Alibaba (BABA US, BUY, TP US$116) Target Price Change]: CMR Improves on Expanded Merchant Base

By Shawn Yang

  • We expect BABA to report C2Q23 (F1Q24) top-line and non-IFRS net income 2% and 21.5% vs. consensus. For C2Q23, we raised (1) Taobao/Tmall GMV/CMR estimates due to return of merchants, 
  • (2) International Commerce and Cainiao revenue estimates, and (3) EBITA margin estimates for all groups except cloud. We maintain our BUY rating and raise TP to US$ 116 TP, 
  • Due to 1) merchants return to Taobao/Tmall;  2) independent listing of groups; and 3) improved incentive structure after the organizational change.

Pre-IPO HighTide Therapeutics – Its Outlook in NASH Field Is Not Optimistic, with High Risks

By Xinyao (Criss) Wang

  • The mechanism of NASH has not yet been accurately determined. Among the major players, FDA has postponed the approval of OCA (FXR) for NASH. THR-β is currently the most promising. 
  • HighTide claims that HTD1801 is able to achieve the goal of improving effectiveness and reducing toxicity. However, HTD1801 hasn’t reached pathological endpoints. We’ll have to wait for future clinical data.
  • This Company actually has high risk due to cash shortage and uncertain R&D progress, which could lead to lower-than-expected stock price performance. We are conservative about HighTide based on analysis.

Morning Views Asia: China SCE, Hopson Development, Reliance Industries, Sino-Ocean Service

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


PDD Holdings Inc.: 3 Major Factors Responsible For Its Recovery – Key Drivers

By Baptista Research

  • PDD delivered an all-around beat in the previous quarter and the company saw clear recovery trends.
  • Revenue increased in the quarter and contributed to a total of RMB37.6 billion.
  • PDD has also launched its electronic shopping season and invested millions of RMB for promoting universal and high-quality access to reading.

Syngenta Pre-IPO – The Positives – Giant in the Agriculture Industry Set to Benefit from Policies

By Clarence Chu

  • Syngenta Group (1844795D CH) is looking to raise around US$9.2bn in its upcoming China A-share IPO.
  • Syngenta Group (Syngenta) is one of the largest agricultural firms globally, developing, producing and commercializing a portfolio of crop protection, seeds, crop nutrition products.
  • In this note, we will talk about the positive aspects of the deal.

Unisound AI Technology Pre-IPO Tearsheet

By Ethan Aw

  • Unisound AI Technology (1053075D CH) is looking to raise at least US$300m in its upcoming HK IPO. The deal will be run by CICC and Haitong International.
  • The firm offers AI solutions centered around its computing cluster, scheduling computing power for machine learning tasks. It provides support to the development, optimization and commercialization of frontier AI models. 
  • Its computing cluster currently harbors a computing power of over 200 peta floating point operations per second (PFLOPS), and a storage capacity of over 1.6 petabytes (PB). 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars